SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer headquartered in Sydney, Australia, on September 28, 2016. The filing serves to distribute the company's Annual Report 2016, Appendix 4G, and Corporate Governance Statement to the U.S. Securities and Exchange Commission. The registrant files annual reports under Form 20-F.
Financial Metrics
The provided text contains only the cover page and exhibit index of the Form 6-K. It does not include the actual financial statements or the content of the attached Annual Report. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
Material Changes
The filing text does not provide data regarding material changes versus prior periods. The document acts solely as a vehicle to submit the attached exhibits.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, and contingencies are not detailed in the cover page text. These items are expected to be contained within the attached Exhibit 99.1 (Annual Report 2016), which is not included in the input source.
Key Facts for Investor Verification
- The filing date is September 28, 2016, for Prima BioMed Ltd.
- The filing includes the Annual Report 2016 as Exhibit 99.1.
- The company is authorized by Marc Voigt, Chief Executive Officer.
- Critical financial data and operational updates are located in the attached exhibits, not in the Form 6-K cover text.